Objective: To investigate the effect of recombinant human brain natriuretic peptide on patients with non-ST segment elevation acute coronary syndrome. Methods: 80 patients with non-ST segment elevation acute coronary syndrome diagnosed and treated in our hospital from January 2017
to December 2019 were randomly divided into study group (n = 41) and control group (n = 39). All patients were treated with basal therapy, the control group was treated with isosorbide dinitrate, and the study group was treated with recombinant human brain natriuretic peptide on the basis
of the control group. The changes of cardiac function indexes, renal function indexes and hemodynamic parameters before and after treatment were observed and compared between the two groups. Results: The total effective rate of the study group was 87.80%, which was significantly higher than
that of the control group (69.23%) (P<0.05). There was no significant difference in left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD) and left ventricular ejection fraction (LVEF), hemodynamic parameters’ cardiac index (CI), central
venous pressure (CVP), mean arterial pressure (MAP), systemic vascular resistance index (SVRI) and glomerular filtration rate (eGFR) between the two groups before treatment (P>0.05). After treatment, LVEDD, LVESD and SVRI were all decreased than that before treatment in the two groups,
LVEF, CI, CVP, MAP and eGFR were higher than those before treatment (P<0.05), and LVEDD, LVESD and SVRI in the study group were lower than those in the control group, and LVEF, CI, CVP, MAP and eGFR were higher than those in the control group (P<0.05). Conclusion: Recombinant human brain
natriuretic peptide is effective in the treatment of non-ST segment elevation acute coronary syndrome, which is beneficial not only for the recovery of cardiac function, but also for the improvement of hemodynamic staus and renal function.
